Review of the Expert Council “Multiple myeloma: the era of monoclonal antibodies in the treatment of patients with multiple myeloma”
Author:
Abstract
Publisher
Publishing House ABV Press
Subject
Oncology,Hematology
Reference17 articles.
1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. NEJM. Available at: https://www.nejm.org/doi/ full/10.1056/nejmoa2024850 (accessed January 9, 2024).
2. Berdeja J.G., Madduri D., Usmani S.Z. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021;398(10297):314–24. DOI: 10.1016/S0140-6736(21)00933-8
3. Cohen A.D., Mateos M.V., Cohen Y.C. et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 2023;141(3): 219–30. DOI: 10.1182/blood.2022015526
4. Munshi N.C., Avet-Loiseau H., Anderson K.C. et al. A large metaanalysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 2020;4(23):5988–99. DOI: 10.1182/bloodadvances.2020002827
5. Moreau P., Dimopoulos M.A., Mikhael J. et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021;397(10292):2361–71. DOI: 10.1016/S0140-6736(21)00592-4
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3